1. Signaling Pathways
  2. Metabolic Enzyme/Protease
  3. Aldose Reductase

Aldose Reductase

Aldose reductase is a small, cytosolic, monomeric enzyme which belongs to the aldo-keto reductase superfamily. Aldose reductase catalyzes the reduced form of nicotinamide adenine dinucleotide phosphate (NADPH)-dependent reduction of a wide variety of aromatic and aliphatic carbonyl compounds. It is implicated in the development of diabetic and galactosemic complications involving the lens, retina, nerves, and kidney.

Aldose reductase is both the key enzyme of the polyol pathway, whose activation under hyperglycemic conditions leads to the development of chronic diabetic complications, and the crucial promoter of inflammatory and cytotoxic conditions, even under a normoglycemic status. Aldose reductase represents an excellent drug target and a huge effort is being done to disclose novel compounds able to inhibit it.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-N0102
    Isoliquiritigenin
    Inhibitor 98.07%
    Isoliquiritigenin is an anti-tumor flavonoid from the root of Glycyrrhiza uralensis Fisch., which inhibits aldose reductase with an IC50 of 320 nM. Isoliquiritigenin is a potent inhibitor of influenza virus replication with an EC50 of 24.7 μM.
    Isoliquiritigenin
  • HY-66009
    Epalrestat
    Inhibitor 99.36%
    Epalrestat is an orally active aldose reductase inhibitor that acts on diabetic neuropathy.
    Epalrestat
  • HY-N0033
    Poliumoside
    Inhibitor 99.80%
    Poliumoside, a caffeoylated phenylpropanoid glycoside, is isolated from Brandisia hancei stems and leaves. Poliumoside is an advanced glycation end product (AGE) formation and rat lens aldose reductase (RLAR) inhibitor, with IC50s of 19.69 and 8.47 μM, respectively. Poliumoside also has antiinflammatory and antioxidant activity.
    Poliumoside
  • HY-122652
    MitoBloCK-6
    Inhibitor 98.07%
    MitoBloCK-6 is a potent Erv1/ALR inhibitor, with an IC50 of 900 nM and 700 nM, respectively. MitoBloCK-6 also inhibits Erv2 (IC50=1.4 μM). MitoBloCK-6 can induce Apoptosis via cytochrome c release. MitoBloCK-6 inhibits growth of developing zebrafish motor neurons. MitoBloCK-6 has anticancer activity against liver cancer and leukemia.
    MitoBloCK-6
  • HY-105185
    Fidarestat
    Inhibitor 99.63%
    Fidarestat (SNK 860) is an inhibitor of aldose reductase, with IC50s of 26 nM, 33 μM, and 1.8 μM for aldose reductase, AKR1B10 and V301L AKR1B10, respectively; Fidarestat (SNK 860) has the potential to treat diabetic disease.
    Fidarestat
  • HY-176719
    AKR1B1/STAT3/SLC7A11-regulator-1
    Inhibitor
    AKR1B1/STAT3/SLC7A11-regulator-1 (5a) is an AKR1B1/STAT3/SLC7A11 regulator that reverses DOX resistance in MCF-7/ADR cells by enhancing ferroptosis activity. AKR1B1/STAT3/SLC7A11-regulator-1 can be used in breast cancer research.
    AKR1B1/STAT3/SLC7A11-regulator-1
  • HY-176084
    RJG-2051
    Inhibitor
    RJG-2051 is a selective covalent aldo-keto reductase family 1 member C3 (AKR1C3) inhibitor with an IC50 value of 13 nM. RJG-2051 interferes with the metabolic process of substrates such as androgens, estrogens, and prostaglandins by AKR1C3. RJG-2051 is promising for research of cancers.
    RJG-2051
  • HY-105185B
    (Rac)-Fidarestat
    Inhibitor
    (Rac)-Fidarestat ((Rac)-SNK 860) is the racemate of Fidarestat (HY-105185). (Rac)-Fidarestat is a potent aldose reductase inhibitor.
    (Rac)-Fidarestat
  • HY-50289
    Sorbinil
    Inhibitor 99.85%
    Sorbinil is an aldose reductase inhibitor (ARI) that prevents the accumulation of sorbitol in cells or animals. Sorbinil is useful in studying diabetes and diabetic complications, reducing AR activity and inhibiting the polyol pathway.
    Sorbinil
  • HY-150644
    S07-2010
    Inhibitor 98.35%
    S07-2010 is a potent pan-AKR1C (aldo-keto reductase family 1 member C) inhibitor, with IC50 values of 0.19, 0.36, 0.47, and 0.73 μM for AKR1C3, AKR1C4, AKR1C1 and AKR1C2, respectively. S07-2010 induces apoptosis in A549/DDP cells. S07-2010 strengthens the cytotoxicity of chemotherapeutic agents in drug-resistant cells. S07-2010 significantly inhibits the proliferation of drug-resistant cells.
    S07-2010
  • HY-106697
    Ponalrestat
    Inhibitor 99.51%
    Ponalrestat (ICI 128436) is an orally active, selective and noncompetitive aldose reductase (AKR1B1; ALR) inhibitor. Ponalrestat selectively inhibits ALR2 (Ki=7.7 nM) over ALR1 (Ki=60 μM). Ponalrestat inhibits the conversion of glucose to sorbitol.
    Ponalrestat
  • HY-16500
    Tolrestat
    Inhibitor 99.37%
    Tolrestat is a potent, orally active aldose reductase inhibitor with IC50 of 35 nM.
    Tolrestat
  • HY-114009
    AKR1C1-IN-1
    Inhibitor 99.38%
    AKR1C1-IN-1 is a potent and selective inhibitor of human 20α-hydroxysteroid dehydrogenase (AKR1C1), with a Ki value of 4 nM for AKR1C1.
    AKR1C1-IN-1
  • HY-N0310
    Soyasaponin Bb
    Inhibitor 99.13%
    Soyasaponin Bb is an orally active, covalent inducer of heme oxygenase HO-1 and an inhibitor of aldose reductase AKR1B1. Soyasaponin Bb can regulate oxidative stress pathways, enhance antioxidant capacity, reduce reactive oxygen species (ROS) generation, and inhibit lipid peroxidation and hepatocyte apoptosis. Soyasaponin Bb improves alcohol-induced hepatocyte membrane damage and liver function abnormalities, and improves Scopolamine (HY-N0296)-induced memory impairment. Soyasaponin Bb has antioxidant, hepatoprotective, and neuroprotective activities.
    Soyasaponin Bb
  • HY-N0539
    Calceolarioside B
    99.93%
    Calceolarioside B is a natural product isolated from Akebia quinata leaves. Calceolarioside B exhibits significant inhibitory activity against rat lens aldose reductase (RLAR) with an IC50 of 23.99 μM. Calceolarioside B displays inhibitory effect on DPPH radical scavenging activity with an IC50 of 94.60 μM .
    Calceolarioside B
  • HY-139696
    AKR1B10-IN-1
    Inhibitor
    AKR1B10-IN-1 is a potent inhibitor of AKR1B10 (Aldo-Keto Reductase 1B10) with an IC50 of 3.5 nM. AKR1B10-IN-1 suppresses proliferation, metastasis, and Cisplatin (CDDP) resistance of lung cancer cells.
    AKR1B10-IN-1
  • HY-133708
    β-Glucogallin
    Inhibitor 99.82%
    β-Glucogallin is an orally active and selective aldose reductase (AKR1B1) inhibitor with an IC50 value of 58 μM when using Glyceraldehyde (HY-128748) as AKR1B1 substrate. β-Glucogallin reduces ROS, PDGF, RAGE, and NF-κB. β-Glucogallin increases SOD. β-Glucogallin has antioxidant and hepatoprotective effects. β-Glucogallin can be used in retinal research.
    β-Glucogallin
  • HY-N1517
    Ganoderic acid C2
    99.72%
    Ganoderic acid C2 is a bioactive triterpenoid in Ganoderma lucidum. Ganoderic acid C2 possesses the potential anti-tumor bioactivity, antihistamine, anti-aging and cytotoxic effects. Ganoderic acid C2 is the inhibitor for aldose reductase with an IC50 of 43.8 µM.
    Ganoderic acid C2
  • HY-N4089
    Quercetin 3-gentiobioside
    Inhibitor 99.92%
    Quercetin 3-gentiobioside is isolated from A. iwayomogi, AR and AGE formation inhibitor, demonstrates biological activities against Aldose reductase (AR) and the formation of advanced glycation endproducts (AGEs).
    Quercetin 3-gentiobioside
  • HY-N0311
    Emodin-8-glucoside
    Inhibitor 99.35%
    Emodin-8-glucoside is an anthraquinone derivative that can be isolated from Aloe vera. Emodin-8-glucoside is the inhibitor for MAPK with an inhibition constant of 430.14 pM. Emodin-8-glucoside exhibits moderate inhibitory activity against rat lens aldose reductase (ALAR) and topoisomerases II with IC50s of 14.4 μM and 66 μM. Emodin-8-glucoside exhibits antioxidant, anti-inflammatory and anti-fibrotic activities. Emodin-8-glucoside can cross the blood brain barrier.
    Emodin-8-glucoside
Cat. No. Product Name / Synonyms Application Reactivity